Abstract
|
Result of a Pilot External Quality Assessment Scheme for Clinical Diagnosis of Inherited Metabolic Disorders in China
by Yuxuan Du, Panpan Jiang, Jiangtao Yang, Ming Zhao, Liping Wu, Yufan Hui, Guoxing Geng, Guangrui Lai, Wei Li, Jiuzhong Mao, Min Zhang, Xiang Ji,
Li Qiu, Yi Liu, Xinhui Gan, Dongxiao Li, Hongqin He, Xiangju Liu, Yanmin Wang, Shengju Hao, Pengyi Zhang, Chaowen Yu, Jingkun Miao, Yongmei Jiang, Xuefan Gu, Jianhui Jiang, Bijun Zhang, Xiaojian Wang, Zhiguo Wang, Wei Wang, Yanling Yang
|
|
|
Background: We aimed to evaluate the diagnostic capabilities of Chinese laboratories for inherited metabolic disorders (IMDs) using gas chromatography-mass spectrometry (GC-MS) on urine samples. Meanwhile, based on the result of the pilot external quality assessment (EQA) scheme, we hope to establish a standardized and reliable procedure for future EQA practice.
Methods: We recruited laboratories that participated in the EQA of quantitative analysis of urinary organic acids with GC-MS before joining the surveys. In each survey, a set of five real urine samples was distributed to each participant. The participants should analyze the sample by GC-MS and report the "analytical result", “the most likely diagnosis”, and "recommendation for further tests" to the NCCL before the deadline.
Results: A total of 21 laboratories participated in the scheme. The pass rates were 94.4% in 2020 and 89.5% in 2021. For all eight IMDs tested, the analytical proficiency rates ranged from 84.7% - 100%, and the interpretational performance rate ranged from 88.2% - 97.0%. The performance on hyperphenylalaninemia (HPA), 3-methylcrotonyl-CoA carboxylase deficiency (MCCD), and ethylmalonic encephalopathy (EE) samples were not satisfactory.
Conclusions: In general, the participants of this pilot EQA scheme are equipped with the basic capability for qualitative organic acid analysis and interpretation of the results. Limited by the small size of laboratories and samples involved, this activity could not fully reflect the state of clinical practice of Chinese laboratories. NCCL will improve the EQA scheme and implement more EQA activities in the future.
DOI: 10.7754/Clin.Lab.2023.230909
|
